Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases.
Although most classical Hodgkin lymphoma patients are cured, a significant minority fail after primary therapy and may die as result of their disease. To date, there is no consensus on biological markers that add value to usual parameters (which comprise the International Prognostic Score) used at diagnosis to predict outcome. We evaluated 59 patients (18 with primary refractory or early relapse disease and 41 responders) for bcl2, Ki67, CD20, TiA1 and c-kit expression by semi-quantitative immunohistochemical study and correlated the results with the response to treatment.The results showed that expression of bcl2 and CD20 in Hodgkin and Reed Sternberg cells, and expression of TiA1 in micro-environmental lymphocytes, and c-kit positive mast cells in microenvironment, were independent prognostic markers. These novel cHL markers could be used in association with clinical parameters to identify newly diagnosed patients with favorable or unfavorable prognosis and to better tailor treatment for different risk groups.
Canioni
Danielle
D
Department of Pathology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, University Paris-Descartes, Faculté de Médecine, Paris, France. danielle.canioni@nck.aphp.fr
Deau-Fischer
Bénédicte
B
Taupin
Pierre
P
Ribrag
Vincent
V
Delarue
Richard
R
Bosq
Jacques
J
Rubio
Marie-Thérèse
MT
Roux
Damien
D
Vasiliu
Viorel
V
Varet
Bruno
B
Brousse
Nicole
N
Hermine
Olivier
O
D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D006689:Hodgkin Disease / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011379:Prognosis
D014408:Biomarkers, Tumor